BioSpace News Archive

Aria Pharmaceuticals secured six provisional patents to cover the lead drug candidates for its lupus, idiopathic pulmonary fibrosis and chronic kidney disease research programs.

Pfizer signaled its interest in longevity research through a new partnership -and a $500,000 investment - in a decentralized drug development program driven by VitaDAO.

Vilya will use its funds for cutting-edge computational techniques to develop innovative drugs for difficult-to-treat diseases.

Umoja CEO Andy Scharenberg spoke with BioSpace about the company’s unique tri-platform approach to immunotherapy which aims to attack and destroy hematologic and solid organ-based tumors.

Jounce Therapeutics announced that a Phase II trial assessing a combination treatment for non-small cell lung cancer failed to meet its primary endpoint.

Avid Bioservices, Inc. (NASDAQ:CDMO), today announced that it will report financial results for the first quarter of fiscal year 2023 on September 6, 2022 after market close and will host a webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time).

Amgen (NASDAQ: AMGN) today announced that the global Phase 3 CodeBreaK 200 trial evaluating once daily oral LUMAKRAS® (sotorasib) met its primary endpoint of progression-free survival (PFS), demonstrating statistical significance and superiority over standard of care chemotherapy, intravenous docetaxel.

Quince Therapeutics, Inc. (Nasdaq: QNCX), today presented preclinical data at the 14th International Conference on Osteogenesis Imperfecta (OI 2022) demonstrating the potential of its novel targeted therapeutic NOV004 to treat fracture in osteogenesis imperfecta (OI) by promoting accelerated increases in bone density, strength, and healing directly at the site of bone fracture.

ANI Pharmaceuticals, Inc. (“ANI” or “the Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present at the H.C. Wainwright 24th Annual Global Investment Conference.

Invitae, a leading medical genetics company, announced that members of its management team will participate in the following investor conference.